{"pageContent": "Background: Androgen-deprivation therapy (ADT) by either a gonadotropin-releasing hormone (GnRH) agonist or bilateral orchiectomy improves disease-related outcomes of men with prostate cancer but has a variety of adverse metabolic effects including obesity, increased abdominal girth, increased triglycerides, and insulin resistance. Each is a risk factor for gallstone disease. Additionally, GnRH agonist treatment was recently shown in metabolomic analyses to increase plasma levels of some bile acids.", "metaData": {"source": "The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma\nhttps://pubmed.ncbi.nlm.nih.gov/10898342/"}}